US 11,738,021 B2
Composition and method for preventing, alleviating or treating cancer
Ki Cheong Park, Lowell, MA (US); and Seokmo Kim, Lowell, MA (US)
Assigned to CKP THERAPEUTICS, INC., Lowell, MA (US)
Filed by CKP Therapeutics, Inc., Lowell, MA (US)
Filed on Aug. 23, 2021, as Appl. No. 17/409,233.
Prior Publication US 2023/0102831 A1, Mar. 30, 2023
Int. Cl. A61K 31/4745 (2006.01); A61K 31/395 (2006.01); A61P 35/00 (2006.01); A61K 33/243 (2019.01); A61K 31/282 (2006.01); A61K 31/337 (2006.01); A61K 31/44 (2006.01); A61K 31/475 (2006.01); A61K 31/506 (2006.01); A61K 31/513 (2006.01); A61K 31/519 (2006.01); A61K 31/5377 (2006.01); A61K 31/704 (2006.01); A61K 31/7068 (2006.01); A61K 38/17 (2006.01); A61K 38/21 (2006.01); A61K 39/395 (2006.01)
CPC A61K 31/4745 (2013.01) [A61K 31/282 (2013.01); A61K 31/337 (2013.01); A61K 31/44 (2013.01); A61K 31/475 (2013.01); A61K 31/506 (2013.01); A61K 31/513 (2013.01); A61K 31/519 (2013.01); A61K 31/5377 (2013.01); A61K 31/5545 (2017.08); A61K 31/704 (2013.01); A61K 31/7068 (2013.01); A61K 33/243 (2019.01); A61K 38/179 (2013.01); A61K 38/212 (2013.01); A61K 39/3955 (2013.01); A61P 35/00 (2018.01)] 14 Claims
 
1. A method for enhancing sensitivity of a subject to an anticancer drug, comprising administering to the subject a pharmaceutical composition containing, as an active ingredient, 1-(2-fluorophenyl)-4,6-dimethyl-1H,2H,3H-pyrrolo[3,2-c]quinoline represented by the following Formula 1 or a pharmaceutically acceptable salt thereof:

OG Complex Work Unit Chemistry